The conference is the final highlight of the Computational ONcology TRaining Alliance (CONTRA), an EU-funded Innovative Training Network. It aims to bring together investigators in the broader scope of oncology for talks and discussion on practical problems and latest research. We expect participants from different backgrounds including statistics, bioinformatics, imaging, and biomedical sciences.
The conference will involve a single track with 8 keynote speakers as well as contributed talks. The number of participants is limited to 100 to enable easy interactions and networking between participants.
Additionally, there will be two conference dinners and free afternoons for enjoying winter sports in the Swiss Alps together.
When: 11.04.22 - 13.04.22
Where: Radisson Blu - Andermatt
Registration Fee: 425 CHF (+7.7% VAT for companies/individuals)
Registration: 07.02.21 - 13.03.22, 11:59pm
Integration of different high-throughput molecular datasets in order to build comprehensive molecular models of disease that can help clinicians to provide better diagnoses and suggest personalized therapies.
Researching factors that favor or veto selection of specific alterations, with focus on concurrent or mutually exclusive selection and its' impact on therapy response. Understanding cancer cell plasticity induced by epigenetic and transcriptional reprogramming among and within patients with single-cell and spatial -omics technologies.
Investigating molecular heterogeneity of tumor subtypes and the role of the cancer microenvironment in disease progression and drug resistance through the high-throughput whole genome data, with a particular focus on meta analysis and the integration of multiple sources of data.
Usage of high throughput sequencing to study the regulation of T and B cell receptor repertoire diversity with focus on the immune response to cancer, and to major pathogens including HIV and Mycobacterium tuberculosis.
Investigating mechanisms of cellular damage to understand their consequences for human health and disease with experimental and computational approaches. Studying normal and diseased cells and tissues to identify molecular mechanisms which are dysregulated in disease, including cancer.
Investigating mutational signatures as a consequence of DNA repair, and how these can be used to study the etiology of cancer.
Focusing on the study of cancer from a genomics perspective, with particular interest in the identification of cancer driver mutations, genes and pathways across tumour types and in the study of their potential as therapeutic targets.
Focusing on the molecular evolution of genomes, cells, populations, and species, combining concepts and tools from biology, statistics, and computer science. Working on the phylogenetic analysis of genes and genomes, including the selection of models of nucleotide evolution, phylogeography, and estimation of species trees.
|Niko Beerenwinkel||ETH Zurich|
|Jens Lagergren||KTH Stockholm|
|Ewa Szczurek||University of Warsaw|
|Nico Borgsmüller||ETH Zurich|
|Arhur Dondi||ETH Zurich|
|Iwona Zielinska||University of Warsaw|